Free Trial

Prime Medicine (PRME) Stock Price, News & Analysis

Prime Medicine logo
$3.18 +0.27 (+9.28%)
As of 04:00 PM Eastern

About Prime Medicine Stock (NYSE:PRME)

Key Stats

Today's Range
$2.88
$3.24
50-Day Range
$2.64
$3.96
52-Week Range
$2.56
$9.77
Volume
1.66 million shs
Average Volume
878,147 shs
Market Capitalization
$417.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.13
Consensus Rating
Buy

Company Overview

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Prime Medicine Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
74th Percentile Overall Score

PRME MarketRank™: 

Prime Medicine scored higher than 74% of companies evaluated by MarketBeat, and ranked 286th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Prime Medicine has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Prime Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Prime Medicine's stock forecast and price target.
  • Earnings Growth

    Earnings for Prime Medicine are expected to grow in the coming year, from ($1.68) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prime Medicine is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prime Medicine is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prime Medicine has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for PRME.
  • Dividend Yield

    Prime Medicine does not currently pay a dividend.

  • Dividend Growth

    Prime Medicine does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for PRME.
  • News Sentiment

    Prime Medicine has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Prime Medicine this week, compared to 3 articles on an average week.
  • Search Interest

    Only 6 people have searched for PRME on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Prime Medicine insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.47% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Prime Medicine's insider trading history.
Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

PRME Stock News Headlines

StockNews.com Upgrades Prime Medicine (NYSE:PRME) to Sell
Now that Trump’s be inaugurated, this day will be key (mark your calendar)
Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO the market… Unleashing more explosive moves than ever before.
See More Headlines

PRME Stock Analysis - Frequently Asked Questions

Prime Medicine's stock was trading at $2.92 at the beginning of the year. Since then, PRME stock has increased by 8.9% and is now trading at $3.18.
View the best growth stocks for 2025 here
.

Prime Medicine, Inc. (NYSE:PRME) posted its earnings results on Tuesday, November, 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.01. The company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $55 million.

Prime Medicine (PRME) raised $175 million in an IPO on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share.

Prime Medicine's top institutional shareholders include Green Alpha Advisors LLC (0.05%), SG Americas Securities LLC (0.05%), Avanza Fonder AB (0.02%) and Impact Partnership Wealth LLC (0.01%). Insiders that own company stock include Robert Nelsen and 2019 Gp LLC Gv.
View institutional ownership trends
.

Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Intel (INTC), NVIDIA (NVDA), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/12/2024
Today
1/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
234
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.13
High Stock Price Target
$18.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+312.7%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

Net Income
$-198,130,000.00
Pretax Margin
-27,406.12%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.37 per share

Miscellaneous

Free Float
100,378,000
Market Cap
$417.09 million
Optionable
Optionable
Beta
1.86
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NYSE:PRME) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners